At the news
? NEUTRALIMPACT 5/10 8-K filed Apr 3, 2026 at 14:43 ET
Denali Therapeutics announced that Takeda has terminated their 2018 collaboration agreement to co-develop and co-commercialize DNL593 for frontotemporal dementia, citing strategic reasons unrelated to efficacy or safety. Denali will regain full rights to the program and continue its clinical development independently, with Phase 1/2 data expected by end of 2026.
- Takeda terminated the 2018 collaboration agreement for DNL593 (PTV:PGRN) for FTD-GRN due to strategic considerations, not efficacy or safety issues
- All rights to DNL593 will revert to Denali 60 days after the April 3, 2026 notice
- Denali will have no further financial obligations to Takeda post-termination
- Denali plans to continue clinical development of DNL593 independently
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access